• Explore /
  • Poster
  • / Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced gastric and gastroesophageal junction adenocarcinoma (SGNLVA-005, Trial-in-Progress).

Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced gastric and gastroesophageal junction adenocarcinoma (SGNLVA-005, Trial-in-Progress).

Abstract Video & Slides Poster

Authors

null

Amna Falak Sher

Stony Brook University Hospital, Stony Brook, NY

Amna Falak Sher , Justine Yang Bruce , Sung Yong Oh , Ian Churchill Anderson , Do-Youn Oh , Louise M. Nott , Jong-Seok Lee , Chia-Chi Lin , Ranee Mehra , Byoung Yong Shim , Wu-Chou Su , Troy H. Guthrie , Nashat Y. Gabrail , Rachel E. Sanborn , Arielle Shebay Lee , Diego Luigi Cortinovis , Paul Swiecicki , Yinghui Wang , Zejing Wang , Jae Yong Cho

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Esophageal and Gastric Cancer

Track

Esophageal and Gastric Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04032704

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr TPS256)

DOI

10.1200/JCO.2021.39.3_suppl.TPS256

Abstract #

TPS256

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Amna Falak Sher

First Author: Julie E. Bauman

First Author: Hiroya Taniguchi

Poster

2023 ASCO Annual Meeting

A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.

A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.

First Author: Jordi Rodon Ahnert